{"entity":{"id":"nct05770531","kind":"trial","name":"Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy","aka":[],"tldr":"A phase 2 trial of sacituzumab govitecan in triple-negative breast cancer, run by Vanderbilt-Ingram Cancer Center, now recruiting.","summary":"Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy is a phase 2, randomised interventional study registered as NCT05770531 by Vanderbilt-Ingram Cancer Center, with a registry enrolment figure of 160 participants, started 2023-10-03 and due to reach its primary completion in 2028-08-01. Interventions recorded: Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Biospecimen Collection; Sacituzumab Govitecan. Conditions listed: Metastatic HER2-Negative Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma. Triple-negative eligibility wording from the registry: \"* Malignancies other than TNBC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05770531","url":"https://clinicaltrials.gov/study/NCT05770531"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05770531","phase":"2","setting":"A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast Cancer","sponsor":"Vanderbilt-Ingram Cancer Center","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05770531/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}